2023
Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial
Jamil Y, Park D, Verde L, Sherwood M, Tehrani B, Batchelor W, Frampton J, Damluji A, Nanna M. Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial. The American Journal Of Cardiology 2023, 214: 66-76. PMID: 38160927, PMCID: PMC10923116, DOI: 10.1016/j.amjcard.2023.12.045.Peer-Reviewed Original ResearchStable ischemic heart diseaseAnti-anginal agentIntensive medical therapyIschemic heart diseaseMedical therapyQOL metricsHeart diseaseFindings merit further researchMajor adverse cardiovascular eventsAnti-anginal treatmentBARI 2D trialGreater QoL improvementAdverse cardiovascular eventsMyocardial jeopardy indexCardiovascular eventsCause mortalityCardiovascular endpointsClinical confoundersPatient characteristicsDiabetes mellitusHeart failureTherapy intensityClinical outcomesQOL improvementMyocardial infarctionComparison of intravascular ultrasound, optical coherence tomography, and conventional angiography‐guided percutaneous coronary interventions: A systematic review, network meta‐analysis, and meta‐regression
Park D, An S, Jolly N, Attanasio S, Yadav N, Gutierrez J, Nanna M, Rao S, Vij A. Comparison of intravascular ultrasound, optical coherence tomography, and conventional angiography‐guided percutaneous coronary interventions: A systematic review, network meta‐analysis, and meta‐regression. Catheterization And Cardiovascular Interventions 2023, 102: 440-450. PMID: 37483068, PMCID: PMC10908343, DOI: 10.1002/ccd.30784.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsPercutaneous coronary interventionOptical coherence tomographyCoronary angiographyIntravascular ultrasoundCoronary interventionCardiac deathClinical outcomesClinical efficacyConventional angiography-guided PCIAngiography-guided percutaneous coronary interventionCoherence tomographyUse of IVUSSuperiority of OCTAdverse cardiovascular eventsRandomized clinical trialsConventional coronary angiographyImaging modalitiesComparative clinical efficacyBest imaging modalityIntracoronary imaging modalityLesion revascularizationPCI guidanceCardiovascular eventsCause mortality
2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsChoice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial
Wang SY, Hanna JM, Gongal P, Onuma O, Nanna MG. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial. American Heart Journal 2022, 254: 30-34. PMID: 35932912, PMCID: PMC10908340, DOI: 10.1016/j.ahj.2022.07.006.Peer-Reviewed Original ResearchConceptsDiastolic hypertensionSystolic hypertensionAntihypertensive agentsSecondary analysisPrevent Heart Attack TrialBroad treatment recommendationsDifferent antihypertensive agentsUse of chlorthalidoneLipid-Lowering TreatmentHeart Attack TrialCoronary heart diseaseCause mortalityPrimary outcomeAttack TrialALLHAT trialHeart diseaseTreatment recommendationsHypertensionPatientsTrialsAntihypertensivesAmlodipineLisinoprilStrokeAgents